250 related articles for article (PubMed ID: 33822368)
1. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Plesner T; Dimopoulos MA; Oriol A; San-Miguel J; Bahlis NJ; Rabin N; Suzuki K; Yoon SS; Ben-Yehuda D; Cook G; Goldschmidt H; Grosicki S; Qin X; Fastenau J; Garvin W; Carson R; Renaud T; Gries KS
Br J Haematol; 2021 Jul; 194(1):132-139. PubMed ID: 33822368
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
[TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Perrot A; Facon T; Plesner T; Usmani SZ; Kumar S; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; He J; Ho KF; Van Rampelbergh R; Uhlar CM; Wang J; Kobos R; Gries KS; Fastenau J; Weisel K
J Clin Oncol; 2021 Jan; 39(3):227-237. PubMed ID: 33326255
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Hungria V; Beksac M; Weisel KC; Nooka AK; Masszi T; Spicka I; Munder M; Mateos MV; Mark TM; Qi M; Qin X; Fastenau J; Spencer A; Sonneveld P; Garvin W; Renaud T; Gries KS
Br J Haematol; 2021 May; 193(3):561-569. PubMed ID: 33555030
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Silbermann R; Laubach J; Kaufman JL; Sborov DW; Reeves B; Rodriguez C; Chari A; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Holstein SA; Costello C; Jakubowiak A; Orlowski RZ; Shain KH; Cowan AJ; Gries KS; Pei H; Cortoos A; Patel S; Lin TS; Voorhees PM; Usmani SZ; Richardson PG
Am J Hematol; 2024 Jul; 99(7):1257-1268. PubMed ID: 38622840
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Bahlis NJ; Dimopoulos MA; White DJ; Benboubker L; Cook G; Leiba M; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Krevvata M; Chiu C; Qin X; Okonkwo L; Trivedi S; Ukropec J; Qi M; San-Miguel J
Leukemia; 2020 Jul; 34(7):1875-1884. PubMed ID: 32001798
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Suzuki K; Dimopoulos MA; Takezako N; Okamoto S; Shinagawa A; Matsumoto M; Kosugi H; Yoon SS; Huang SY; Qin X; Qi M; Iida S
Blood Cancer J; 2018 May; 8(4):41. PubMed ID: 29712896
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Kaufman JL; Dimopoulos MA; White D; Benboubker L; Cook G; Leiba M; Morton J; Joy Ho P; Kim K; Takezako N; Moreau P; Sutherland HJ; Magen H; Iida S; Kim JS; Miles Prince H; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Trivedi S; Casneuf T; Krevvata M; Ukropec J; Kobos R; Avet-Loiseau H; Usmani SZ; San-Miguel J
Blood Cancer J; 2020 Nov; 10(11):111. PubMed ID: 33149130
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.
Weisel K; Ludwig H; Rieth A; Lebioda A; Goldschmidt H
Qual Life Res; 2020 Jan; 29(1):69-79. PubMed ID: 31552577
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Terpos E; Dimopoulos MA; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Pompa A; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Gries KS; Fastenau J; Liu K; He J; Kampfenkel T; Qiu Y; Amin H; Carson R; Sonneveld P
Am J Hematol; 2022 Apr; 97(4):481-490. PubMed ID: 35089607
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Knop S; Mateos MV; Dimopoulos MA; Suzuki K; Jakubowiak A; Doyen C; Lucio P; Nagy Z; Usenko G; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Losava G; Fujisaki T; Garg M; Wang J; Wroblewski S; Kudva A; Gries KS; Fastenau J; San-Miguel J; Cavo M
BMC Cancer; 2021 Jun; 21(1):659. PubMed ID: 34078314
[TBL] [Abstract][Full Text] [Related]
20. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]